Gibson, C. M. Et Al. 2017. The safety and efficacy of full-versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. AMERICAN HEART JOURNAL , vol.185 , 93-100.

Gibson, C. M., Halaby, R., Korjian, S., Daaboul, Y., Arbetter, D. F., Yee, M. K., ... Goldhaber, S. Z.(2017). The safety and efficacy of full-versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. AMERICAN HEART JOURNAL , vol.185, 93-100.

Gibson, C. Et Al. "The safety and efficacy of full-versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial," AMERICAN HEART JOURNAL , vol.185, 93-100, 2017

Gibson, C. M. Et Al. "The safety and efficacy of full-versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial." AMERICAN HEART JOURNAL , vol.185, pp.93-100, 2017

Gibson, C. M. Et Al. (2017) . "The safety and efficacy of full-versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial." AMERICAN HEART JOURNAL , vol.185, pp.93-100.

@article{article, author={C. Michael Gibson Et Al. }, title={The safety and efficacy of full-versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial}, journal={AMERICAN HEART JOURNAL}, year=2017, pages={93-100} }